Welcome to LookChem.com Sign In|Join Free
  • or
19-Norpregna-4,9-dien-20-yn-3-one,17- hydroxy-11-(4-methoxyphenyl)-,(11â,17R)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

67983-55-5

Post Buying Request

67983-55-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

67983-55-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 67983-55-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,9,8 and 3 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 67983-55:
(7*6)+(6*7)+(5*9)+(4*8)+(3*3)+(2*5)+(1*5)=185
185 % 10 = 5
So 67983-55-5 is a valid CAS Registry Number.

67983-55-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 11β-(p-methoxyphenyl)-17β-hydroxy-17α-ethynyl-4,9(10)-estradien-3-one

1.2 Other means of identification

Product number -
Other names 11β-p-methoxyphenyl-17β-hydroxy-17α-ethinyl-4,9-(10)-estradien-3-one

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:67983-55-5 SDS

67983-55-5Relevant academic research and scientific papers

Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding

-

, (2008/06/13)

Competitive progesterone antagonists (antigestagens) are suitable for the production of pharmaceutical agents for the treatment of forms of dysfunctional uterine bleeding (metrorrhagias, menorrhagias, hypermenorrhea).

Method for treating endometriosis or leiomyomata uteri with a competitive progesterone antagonist and a gestagen

-

, (2008/06/13)

PCT No. PCT/EP95/02998 Sec. 371 Date Jun. 10, 1997 Sec. 102(e) Date Jun. 10, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/03130 PCT Pub. Date Feb. 8, 1996This invention relates to the use of a product that contains in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen for its sequential, oral administration, in which each individual dosage unit that contains the competitive progesterone antagonist contains the latter in a non-abortion-inducing amount for the production of a pharmaceutical agent for treating endometriosis or leiomyomata uteri.

REGIO AND STEREOSPECIFIC SYNTHESIS OF 11β-SUBSTITUTED 19-NORSTEROIDS. Influence of 11β-substitution on progesterone receptor affinity.

Belanger, A.,Philibert, D.,Teutsch, G.

, p. 361 - 382 (2007/10/02)

The convenient synthesis of a series of 11β-substituted 17-ethynyl-17β-hydroxy-4,9-estradien-3-ones and their corresponding estradiols is reported.Relative affinities for the progestin and estrogen receptors showed very specific interactions between the p

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 67983-55-5